The E7 Protein Test Kit For Cervical Cancer – A Powerful tool in fighting against Cervical Cancer

The E7 Protein Test Kit for Cervical Cancer

Introduction

The E7 Oncoprotein Test is an innovative, rapid and highly reliable screening solution designed to enhance existing cervical cancer detection methods. Unlike Pap Smears or HPV DNA tests, which identify cellular abnormalities or viral presence, the E7 test directly detects the cancer – driving protein responsible for HPV – related transformation. This enables clinicians to determine whether an HPV infection is actively progressing towards precancerous or cancerous change. For Primary Care Professionals, the result is earlier intervention, fewer unnecessary referrals, greater reassurance for HPV – positive patients, and a faster, more streamlined screening process.

 

Key Advantages of the E7 Oncoprotein Test:

• Sensitivity: 93.75%
• Specificity: 91.3%
• Time to Result: 15 minutes

 

How The E7 Protein Test Kit Works 

1. Take with a sterile swab, a cervical sample
2. Turn the bottle several times:  top to bottom with buffer solution before opening
3. Insert the Swab with the collected material into the bottle and rotate it 10 times, pressing it firmly against the sides of the tube. Remove the swab.
4. Cap the bottle and set aside for 10 minutes for the solution to stabilise. Remove the test cassette and place on a flat surface.
5. Pipette about 100ml of the extracted sample
6. Place 5 drops in the round window marked S on the test cassette
7. Wait for 15 minutes
8. Read the test results, 2 lines means positive

 

Where the E7 Protein Test Kit can be used

• Hospitals & Specialist Clinics – part of colposcopy referral workflows or advanced screening programmes
• Primary Care/ GP Practices – settings capable of point-of-care or near-patient testing, to aid early triage decisions
• Physical examinations Centres or Women’s Health Clinics
• At Home testing

 

How often should patients be tested with the E7 test kit? 

Frequency should be based on clinical judgement and existing cervical screening intervals. For example, every 3 years in women aged 25-49, every 5 years in those aged 50-64.

A Positive E7 result means oncogenic activity is present, and the patient should be referred for coloscopy or further investigation.

 

So Who benefits the most from the E7 Protein Test Kit?

The E7 Oncoprotein test is intended for women aged roughly 18-70 years, particularly those in higher risk categories including:

• Women with positive HPV DNA tests needing further triage
• Patients post-treatment for cervical dysplasia or cancer requiring follow up
• Individuals with impaired immunity
• Women aged over 40, or those with a history of a cervical disease.

Overall, this test kit represents a major advancement in cervical cancer screening, bridging the diagnostic gap between traditional Pap smears and HPV DNA testing. While Pap smears identify abnormal cells and HPV tests confirm viral presence, the E7 test goes a step further – detecting the active, cancer-driving protein that signals the true disease progression. With results being available in just 15 minutes and proven sensitivity and specificity, it offers clinicians faster, more reliable insights into a patient’s real cancer risk. By combining the precision of molecular detection with the speed of point of care testing, the test kit empowers healthcare professionals to make earlier, more confident decisions – delivering greater peace of mind and potentially saving more lives through earlier intervention.